

> ↓ in RBC mass: Hct <41% or Hb <13.5 g/dL (men); Hct <36% or Hb <12 g/dL (women)


# ANEMIA

↓ _in RBC mass: Hct_ <_41% or Hb_ <_13.5 g/dL (men); Hct_ <_36% or Hb_ <_12 g/dL (women)_

臨床表現

• Symptoms: ↓ O2 delivery → fatigue, exertional dyspnea, angina (if CAD)

• Signs: pallor (mucous membranes, palmar creases), tachycardia, orthostatic hypotension

• Other findings: **jaundice** (hemolysis), **splenomegaly** (thalassemia, neoplasm, chronic

hemolysis), **petechiae/purpura** (bleeding disorder), **glossitis** (iron, folate, vitamin B12

defic.), **koilonychia** (iron defic.), **neurologic abnormalities** (B12 defic.)

Diagnostic evaluation

• History: bleeding, systemic illness, drugs, exposures, alcohol, diet (including **pica**), FHx

• CBC with diff.; RBC params incl. retics, MCV (nb, mixed disorder can → 正常 MCV), RDW

• **Reticulocyte index** (RI) = \[reticulocyte count × (Pt’s Hct/nl Hct)\]/maturation factor

maturation factors for a given Hct: 45% = 1, 35% = 1.5, 25% = 2, 20% = 2.5

RI >2% → adequate marrow response; RI <2% → hypoproliferation

• **Peripheral smear:** select area where roughly ⅓ RBCs touch each other; ✔ RBC size, shape, inclusions (see “Appendix” & “Peripheral Smear”), WBC morphology, plt count

• Additional labs as indicated: hemolysis labs (if RI >2%, see below), iron/TIBC, ferritin, folate, B12, LFTs, BUN & Cr, TFTs, Hb electrophoresis, enzyme/gene mutation screens

• **Bone marrow (BM) aspirate and biopsy (bx)** with cytogenetics as indicated

### Figure 5-1 Approach to anemia and common causes

![](https://i.imgur.com/gZlqodj.jpg)

MICROCYTIC ANEMIAS

### Figure 5-2 Approach to microcytic anemias (_NEJM_ 2014;371:1324)

![](https://i.imgur.com/tEgIJNK.jpg)

Iron deficiency (_NEJM_ 2015;372:1832; _Lancet_ 2016;387:907)

• ↓ marrow iron & depleted body iron stores → ↓ heme synthesis → microcytosis → anemia

• Special 臨床表現: angular cheilosis, atrophic glossitis, pica (consumption of nonnutritive substances such as ice, clay), koilonychia (nail spooning)

Plummer-Vinson syndrome (iron deficiency anemia, esophageal web & atrophic glossitis)

• 原因: **chronic bleeding** (GI—incl. cancer, menstrual, parasites, NSAIDs, etc.), ↓ **supply** (malnutrition; ↓ absorp. due to celiac sprue, Crohn’s, ↑ gastric pH, subtotal gastrectomy), ↑ **demand** (preg; _Blood_ 2017;129:940). Iron-refractory iron-defic. anemia (IRIDA; rare genetic disorder due to hepcidin dysregulation; _Nat Genet_ 2008;40:569).

• Diagnosis (eval ideally before Rx): ↓ **Fe**, ↑ **TIBC**, ↓ **ferritin** (esp. <15), ↓ **transferrin sat** (Fe/TIBC; esp. <15%), ↑ soluble transferrin receptor; ↑ plt. Unless hx c/w other etiology, _initiate workup for GIB_, incl. _H. pylori_ serology. ? Celiac labs (**anti-TTG**, antigliadin, anti-endomysial Abs). Cytogenetics & molecular testing as indicated.

• 治療: oral Fe tid (~6 wks to correct anemia; ~6 mo to replete Fe stores; nb, oral Fe does not give ⊕ Hemoccult). In excessive/persistent GI losses or dialysis, cancer, CHF, or prior to Epo Rx, _IV iron_ (Fe-sucrose, -gluconate, -dextran) should be considered.

Thalassemias (_Lancet_ 2018;391:155)

• ↓ synthesis of α- or β-globin chains of Hb → **≠** subunits → destruction of RBCs and erythroid precursors; ∴ anemia from hemolysis _and_ ineffective erythropoiesis

• α**\-thalassemia** (_NEJM_ 2014;371:1908): deletions in α-globin gene complex (nl 4 α genes), seen with Southeast Asian, Mediterranean, African, Middle East ancestry

3 α → α-thal-2 trait = silent carrier; 2 α → α-thal-1 trait or α-thal minor = mild anemia

1 α → HbH (β4) disease = severe anemia, hemolysis, and splenomegaly

0 α genes → Hb Barts (γ4) = intrauterine hypoxia and hydrops fetalis

• β**\-thalassemia:** mutations in β-globin gene → absent or ↓ gene product seen with Mediterranean (espec. Greek or Italian), African, or Asian ancestry

1 mutated β gene → thal minor (or trait) = mild anemia (no transfusions)

2 mutated β genes → thal intermedia (occasional transfusions) or thal major (= Cooley’s anemia; transfusion dependent) depending on severity of mutations

• Special 臨床表現: chipmunk facies, pathologic fractures, hepatosplenomegaly (due to extramedullary hematopoiesis), high-output CHF, bilirubin gallstones, Fe overload

• Dx: MCV <70, **normal Fe, ferritin**, **MCV**/**RBC count** <**13** \[Mentzer Index, 60% Se, 98% Sp; (_Ann Hem_ 2007;86:486)\], ± ↑ retics, basophilic stippling; **Hb electrophoresis:** ↑ HbA2 (α2δ2) in β-thal; _normal_ pattern in α-thal trait, ∴ PCR or supravital stain for dx

• 治療: folate; transfusions + Fe chelator \[either deferoxamine (IV) or deferasirox (PO)\]; ? splenectomy if ≥50% ↑ in transfusions; consider allo-HSCT in children with severe β-thal; gene therapy in development (_NEJM_ 2018;378:1479)

Anemia of chronic inflammation (see below)

Sideroblastic anemia

• Defective heme biosynthesis within RBC precursors

• 原因: **hereditary/X-linked** (_ALAS2_ mutations), **idiopathic**, **MDS-RARS**, **reversible** (alcohol, lead, isoniazid, chloramphenicol, copper deficiency, hypothermia)

• Special 臨床表現: hepatosplenomegaly, iron overload syndromes

• Dx: social, work & TB hx; can be micro-, normo-, or macrocytic; variable populations of hypochromic RBCs; ↑ Fe, 正常 TIBC, ↑ ferritin, basophilic stippling, RBC **Pappenheimer bodies** (Fe-containing inclusions), **ring sideroblasts** (w/ iron-laden mitochondria) in BM

• 治療: treat reversible causes; trial of pyridoxine, supportive transfusions for severe anemia with chelation therapy; high-dose pyridoxine for some hereditary cases

NORMOCYTIC ANEMIAS

Pancytopenia (see below)

Anemia of chronic inflammation (ACI; _NEJM_ 2012;366:4)

• ↓ RBC production due to impaired iron utilization and functional iron deficiency from ↑ **hepcidin;** cytokines (IL-6, TNF-α) cause ↓ Epo responsiveness/production

• 原因: autoimmune disorders, chronic infection, inflammation, HIV, malignancy

• Dx: ↓ **Fe**, ↓ **TIBC (usually normal or low transferrin sat)**, ± ↑ **ferritin;** usually normochromic, normocytic (~70% of cases) but can be microcytic if prolonged

• Coexisting iron deficiency common. Dx clues include ↓ serum ferritin levels, absence of iron staining on BM bx, ⊕ response to a trial of oral iron and/or ↑ soluble transferrin receptor/ferritin index (_Am J Clin Pathol_ 2012;138:642).

• 治療: treat underlying disease ± iron and/or erythropoiesis-stimulating agent (ESA; eg, Epo). Iron if ferritin <100 or Fe/TIBC <20%. Consider ESA if Epo <500. Avoid ESA in cancer if 治療 goal is cure (_Lancet_ 2009;373:1532). Transfuse PRBCs only if symptomatic & insufficient time to wait for response to Epo or underlying disease Rx.

Anemias of other chronic disorders

• Anemia of chronic kidney disease: ↓ Epo; treat with Epo (see “Chronic Kidney Disease”)

• Endocrine deficiencies: hypometabolism and ↓ O2 demand with thyroid, pituitary, adrenal, or parathyroid disease → ↓ Epo; can be normocytic or macrocytic

Sideroblastic anemia (see above)

Pure red cell aplasia

• Destructive antibodies or lymphocytes → ineffective erythropoiesis

• Associated with thymoma, CLL and parvovirus infection, autoimmunity, drugs

• Diagnostic studies: **lack of erythroid precursors on BM bx**, other lines normal

• 治療: thymectomy if thymus enlarged; IVIg if parvovirus and immunosuppressed (_Clin Infect Dis_ 2013;56:968); immuno-suppression/chemoRx if CLL or idiopathic; supportive care with PRBC transfusions; ? erythropoietin receptor agonist if due to antierythropoietin Ab (_NEJM_ 2009;361:1848) consider hematopoietic cell transplantation.

MACROCYTIC ANEMIAS

_includes megaloblastic and nonmegaloblastic causes_

Megaloblastic anemia

• **Impaired DNA synthesis** → cytoplasm matures faster than nucleus → ineffective erythropoiesis and macrocytosis; due to **folate** or **B1****2** **deficiency;** also in **MDS**

• ✔ **folate** and **vitamin B12;** ↑ LDH & indirect bilirubin (due to ineffective erythropoiesis)

• Smear: **neutrophil hypersegmentation**, **macro-ovalocytes**, anisocytosis, poikilocytosis

Folate deficiency

• Folate present in leafy green vegetables and fruit; total body stores sufficient for **2–3 mo**

• 原因: **malnutrition** (alcoholics, anorectics, elderly), ↓ absorption (sprue), impaired metabolism (methotrexate, pyrimethamine, trimethoprim; _NEJM_ 2015;373:1649), ↑ requirement (chronic hemolytic anemia, pregnancy, malignancy, dialysis)

• Diagnosis: ↓ folate; ↓ RBC folate, ↑ homocyst. but 正常 methylmalonic acid (unlike B12 defic.)

• 治療: folate 1–5 mg PO qd for 1–4 mo or until complete hematologic recovery; _critical to r_/_o B_12 _deficiency first (see below)_

Vitamin B12 deficiency (_NEJM_ 2013;368:149)

• B12 present only in foods of animal origin; total body stores sufficient for **2–3 y**

• Binds to **intrinsic factor** (IF) secreted by gastric parietal cells; absorbed in terminal ileum

• 原因: malnutrition (alcoholics, vegans), **pernicious anemia** (PA, autoimmune disease against gastric parietal cells, a/w polyglandular endocrine insufficiency and ↑ risk of gastric carcinoma), other causes of ↓ absorption (gastrectomy, sprue, Crohn’s disease), ↑ competition (intestinal bacterial overgrowth, fish tapeworm)

• 臨床表現: **neurologic** changes (**subacute combined degeneration**) affecting peripheral nerves, posterior and lateral columns of the spinal cord and cortex → numbness, paresthesias, ↓ vibratory and positional sense, ataxia, dementia

• Dx: ↓ B12; ↑ homocysteine and methylmalonic acid; anti-IF Ab; Schilling test; ↑ gastrin in PA

• 治療: 1 mg B12 IM qd × 7 d → q wk × 4–8 wk → q month for life

neurologic abnormalities are reversible if treated within 6 mo

folate can reverse _hematologic_ abnormalities of B12 deficiency but not _neurologic_ changes (and can lead to “steal” of B12 stores → worsening of neuro complications)

oral supplementation (2 mg qd) appears feasible as well (_Cochrane Rev_ CD004655) even without IF

Nonmegaloblastic macrocytic anemias

• **Liver disease:** often macrocytic, may see target cells, or spur cell anemia with hemolysis

• **Alcoholism:** BM suppression & macrocytosis independent of folate/B12 defic. or cirrhosis

• **Reticulocytosis**

• **Other causes:** hypothyroidism; MDS; meds that impair DNA synthesis (zidovudine, 5-FU, hydroxyurea, Ara-C); hereditary orotic aciduria; Lesch-Nyhan syndrome

PANCYTOPENIA

原因

• Hypocellular bone marrow (nl cellularity ~100 – age): **aplastic anemia**, hypoplastic MDS

• Cellular bone marrow: **MDS**, aleukemic leukemia, PNH, severe megaloblastic anemia

• Marrow replacement (myelophthisis): **myelofibrosis**, metastatic solid tumors, granulomas

• Systemic diseases: hypersplenism, sepsis, alcohol, toxins

臨床表現

• Anemia → fatigue

• Neutropenia → recurrent infections

• Thrombocytopenia → mucosal bleeding & easy bruisability

Aplastic anemia = stem cell failure (_NEJM_ 2015;373:35)

• 流行病學: 2–5 cases/106/y; biphasic (major peak in adolescents, 2nd peak in elderly)

• Diagnosis: pancytopenia with ↓ retics, BM bx with cytogenetics showing hypocellularity

• 原因: **idiopathic** (1/2 – 2/3 of cases)

### Stem cell destruction: radiation, **chemotherapy**, **chemicals** (eg, benzene)

Idiosyncratic **med rxn** (eg, chloramphenicol, NSAIDs, sulfa drugs, gold, carbamazepine, antithyroid)

### Viruses (HHV-6, HIV, EBV, parvovirus B19); **post-viral hepatic failure** (not Hep A/B/C)

### Immune disorders (SLE, GVHD post-HSCT, thymoma)

PNH (see below); Fanconi’s anemia (congenital disorder with pancytopenia, macrocytic anemia, ↑ risk of MDS, AML, & SCC of head & neck, and multiple physical anomalies)

Shortened telomeres: seen with telomerase (_TERT, TERC_) mut. (10% of aplastic anemia), dyskeratosis congenita/DKC1 mut; a/w IPF, cirrhosis (_NEJM_ 2009;361:2353)

Somatic mutations: PNH clones in ~50% of aplastic anemia (_Haematologica_ 2010;95:1075)

• 治療 and prognosis

**Allogeneic HSCT:** for _young_ 病人 → ~80% long-term survival and significantly ↓ risk of malignant evolution, but has risk of transplant-related morbidity & mortality; if possible, avoid transfusions (and alloimmunization) pretransplant

### Immunosuppression (CsA/tacrolimus, ATG): 70–80% respond, with 80–90% 5-y survival in responders (96% vs. 76% with horse vs. rabbit ATG; _NEJM_ 2011;365:430); 15–20% 10-y incidence of clonal disorders (mostly MDS, AML, PNH)

### TPO mimetics (eg, eltrombopag) use 1st\-line with immunosuppression (_NEJM_ 2017;376:1540)

**Supportive care:** transfusions, 抗生素, possible utility of G-CSF & Epo (if Epo <500)

Myelodysplastic syndromes (MDS) (qv)

Paroxysmal nocturnal hemoglobinuria (PNH) (_Blood_ 2009;113:6522)

• Acquired clonal stem cell disorder = inactivating somatic mutation of _PIG-A_ gene → deficiency of GPI-anchor for CD55 & CD59 (inhib of complement) → complement-mediated RBC lysis, plt aggreg., & hypercoagulability

• Clinical: intravascular **hemolytic anemia**, **hypercoagulability** (venous > arterial; esp. intraabdominal, cerebral), smooth muscle dystonias, **deficient hematopoiesis** (cytopenias); a/w aplastic anemia, MDS and evolution to AML

• Dx: **flow cytometry** (↓ CD55 & CD59) on RBCs and granulocytes; urine hemosiderosis

• 治療: supportive care (iron, folate, transfusions); consider anticoagulation

allogeneic HSCT for hypoplasia or severe thrombosis

eculizumab (Ab inactivates terminal complement C5s): ↓ hemolysis, improves 生活品質 & stabilizes Hb levels (_NEJM_ 2004;350:552 & 2006;355:1233; _Lancet_ 2009;373:759); effective in pregnancy (_NEJM_ 2015;373:1032); must have meningococcal vaccination

Myelophthisic anemia (see also “Primary Myelofibrosis”)

• Infiltration of bone marrow by cancer, leukemia, infection, fibrosis (primary myelofi- brosis), granulomas, lysosomal storage disorders

HEMOLYTIC ANEMIAS

![](https://i.imgur.com/sgEvmW4.jpg)

Diagnostic evaluation

• ↑ reticulocyte count (RI >2%), ↑ LDH, ↓ haptoglobin (83% Se, 96% Sp), ↑ indirect bili

• Autoimmune hemolysis: Coombs’ test = direct antiglobulin test (DAT) → ⊕ if agglutination occurs when antisera against Ig or C3 are applied to patient RBCs

• Intravascular: ↑↑ LDH, ↓↓ haptoglobin; hemoglobinemia, hemoglobinuria, hemosiderinuria

• Extravascular: splenomegaly

• Family h/o anemia; personal or family h/o cholelithiasis

Glucose-6-phosphate dehydrogenase (G6PD) deficiency (_Lancet_ 2008;371:64)

• X-linked defect of metabolism (_G6PD_ mutations) with ↑ susceptibility to oxidative damage

• Most common in ♂ of African or Mediterranean descent (malaria-endemic areas)

• Hemolysis precipitated by **drugs** (sulfonamides, dapsone, nitrofurantoin, rasburicase, primaquine, doxorubicin, methylene blue), **infxn**, **DKA**, **foods** (favism, _NEJM_ 2018;378:60)

• Diagnosis: smear may show RBC **Heinz bodies** (oxidized Hb) that result in **bite cells** once removed by spleen; ↓ G6PD levels (_may be normal after acute hemolysis_ because older RBCs have already lysed and young RBCs may still have near-normal levels)

Sickle cell anemia (_NEJM_ 2017;376:1561 & _Lancet_ 2017;390:311)

• Recessive β-globin mutation → structurally 異常 hemoglobin (HbS). ~8% African Americans heterozygotes (“sickle trait”; usually without sx); ~1/400 homozygotes (sickle cell disease).

• ↓ O2 → HbS polymerizes → RBC sickles, ↓ RBC deformability → **hemolysis** & **microvascular occlusion** due to endothelial activ. & PMN adhesion (_Blood_ 2013;122:3892)

• **Anemia:** chronic hemolysis ± acute aplastic (parvo. B19) or splenic sequestration crises

• **Vaso-occlusion & infarction:** acute chest syndrome & stroke (high mortality), pulmonary HTN, painful crises, splenic sequestration, renal papillary necrosis, aseptic necrosis, dactylitis (hand-foot syndrome), priapism

• **Infection:** splenic infarction → overwhelming infection by **encapsulated organisms;** infarcted bone → **osteomyelitis** (_Salmonella_, _Staph. aureus_), can be life threatening

• Diagnosis: sickle-shaped RBCs and Howell-Jolly bodies on smear; Hb electrophoresis

• 治療: hydroxyurea, folic acid; ? L\-glutamine to prevent pain crises (_NEJM_ 2018;379:226)

• Vaccines: pneumo, meningo, H flu, HBV

• Voxelotor (Hbs polymerization inhib) ↑ hemolysis to ↑ Hb (_NEJM_ 2019;epub)

• Pain & vaso-occlusive crises: analgesia (consider PCA), IVF, transfusion if sx & Hgb < baseline; crizanlizumab (anti-P-selectin; _NEJM_ 2017;376:429)

• Acute chest: O2, 抗生素, IVF, exchange transfusion

• TIA/stroke: often exchange transfusion (goal Hgb 10) ± thrombolytics

• Gene therapy in development (_NEJM_ 2017;376:848)

Hereditary spherocytosis (HS) (_Lancet_ 2008;372:1411)

• Defect in a cytoskeletal protein of RBC membrane → membrane loss mutations in ankyrin, α- and β-spectrin, band 3, and pallidin have been identified

• Most common in N. European populations (1/5000 births); ⊕ FHx (75% of 病人)

• Anemia, jaundice (mostly neonates), splenomegaly, pigmented gallstones

• Diagnosis: spherocytes on smear, ⊕ osmotic fragility test (~80% Se), ↓ eosin-5-maleimide (EMA) binding (93% Se; 99% Sp; _Haemat_ 2012;97:516), acidified glycerol lysis test (Se 95%)

• 治療: folate, transfusions, splenectomy for moderate and severe HS (balance with ↑ risk of future thrombosis and infection; _J Thromb Haemost_ 2008;6:1289)

Paroxysmal nocturnal hemoglobinuria (see above)

Autoimmune hemolytic anemia (AIHA)

• Acquired, antibody-mediated RBC destruction

• **Warm AIHA: IgG** Abs opsonize RBCs _at body temp_ → removal by spleen

原因: idiopathic, lymphoproliferative (CLL, NHL), autoimmune (SLE), drugs, HIV, Babesiosis (_NEJM_ 2017;376:939)

• **Cold AIHA: IgM** Ab binds to RBCs _at temp_ <_37_°_C_ → **complement fixation** → intravascular hemolysis and acrocyanosis on exposure to cold

原因: idiopathic, lymphoprolif. disorders (eg, Waldenström’s; monoclonal), **_Mycoplasma pneumoniae_** infxn and infectious mononucleosis (polyclonal)

• Diagnosis: spherocytes on smear, ⊕ **Coombs’;** ✔ cold agglutinin titer, splenomegaly

• 治療 (_Blood_ 2017;129:2971): treat underlying disease

**Warm AIHA:** corticosteroids ± splenectomy, IVIg, cytotoxic agents, rituximab

**Cold AIHA:** avoid cold; steroids ineffective; rituximab (_Blood_ 2004;103:2925)

Drug-induced hemolytic anemia

• Acquired, Ab-mediated, RBC destruction precipitated by a med. 抗生素: ceph., sulfa drugs, rifampin, ribavirin. CV: methyldopa, procainamide, quinidine, thiazides. TCAs, phenothiazines, NSAIDs, sulfonylureas, MTX, 5-FU, rasburicase (G6PD defic.)

• Diagnosis: Coombs’ usually negative, ↑ LDH; 治療: discontinue offending agent

Microangiopathic hemolytic anemia (_MAHA_; _NEJM_ 2014;371:654)

• Intra-arteriolar fibrin damages RBCs → acquired intravascular hemolysis

• 原因: **hemolytic-uremic syndrome** (**HUS**), **thrombotic thrombocytopenic purpura** (**TTP**), **disseminated intravascular coagulation** (**DIC**), malignancy, malignant HTN, eclampsia/HELLP, mech. cardiac valves, infected vascular prostheses

• Diagnosis: **schistocytes** ± thrombocytopenia ± abnormalities a/w specific disorders (eg, ↑ PT in DIC, ↑ Cr in HUS, ↑ LFTs in HELLP)

• Rx underlying dx; **urgent plasma exchange with TTP** (replace low ADAMTS13)

Hypersplenism

• Stasis/trapping in spleen → Mφ attack & remodeling of RBC → spherocytosis → hemolysis

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Causes of Splenomegaly</b></p></td></tr><tr><td><p><b>Etiology</b></p></td><td><p><b>Comments<a id="st6"></a><a href="text/part0010_split_000.html#sst6">*</a></b></p></td></tr><tr><td><p>RES hyperplasia</p></td><td><p>Hemolytic anemia, sickle cell disease, <b>thalassemia major</b></p></td></tr><tr><td><p>Immune hyperplasia</p></td><td><p>Infxn [HIV, EBV, CMV, TB, <b>malaria</b>, <b>kala azar</b> (“black water fever” from visceral leishmaniasis), <b><i>Mycobacterium avium</i></b> complex], autoimmune disorders (SLE, RA with Felty’s syndrome), sarcoidosis, serum sickness</p></td></tr><tr><td><p>Congestion</p></td><td><p>Cirrhosis, CHF, portal/splenic vein thrombosis, <b>schistosomiasis</b></p></td></tr><tr><td><p>Infiltration (nonmalignant)</p></td><td><p>Lysosomal storage disorders (<b>Gaucher’s</b>, Niemann-Pick), glycogen storage diseases, histiocytosis X, splenic cysts</p></td></tr><tr><td><p>Neoplasm</p></td><td><p><b>MPN (CML</b>, <b>PMF</b>, <b>PV</b>, <b>ET)</b>, <b>CMML</b>, <b>leukemia</b>, <b>lymphoma (NHL</b>, <b>HL</b>, <b>hairy cell leukemia</b>, <b>CLL</b>, <b>PLL</b>, <b>WM)</b>, T-LGL, myeloma, amyloid</p></td></tr></tbody></table>

RES = reticuloendothelial system; **[\*](text/part0010_split_000.html#st6)boldface** = causes of massive splenomegaly.
